GlaxoSmithKline submits UMEC/VI for approval in EU
9th Jan 2013 12:40
Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the EU for UMEC/VI medicine, a product used to treat chronic obstructive pulmonary disease (COPD). The companies previously announced the submission of a regulatory application in the US on Dec
Read moreLondon close: Stocks finish lower ahead of US budget talks
28th Dec 2012 16:35
Markets finished firmly in negative territory on Friday afternoon as investors showed concern with just a few days left before the fiscal cliff deadline. President Barack Obama has called a meeting with congressional leaders today in which they are expected to draw up a piece of legislation to be s
Read moreLondon midday: Stocks drop into the red as 'fiscal cliff' looms
28th Dec 2012 11:29
After a strong start, markets across Europe dipped into the red by midday with the US fiscal cliff continuing to dominate market sentiment. "We are now just over three days away from the so-called 'fiscal cliff' and after many months of posturing and political bravado, the US has run out of time,"
Read moreThursday newspaper round-up: BAE Systems, Mark Carney, Japan...
20th Dec 2012 06:51
The continued haggling with Saudi Arabia over the price of 48 Eurofighter Typhoon jets could hit full-year profits at BAE Systems. The British defence contractor said that negotiations with the Royal Saudi Air Force about the price of the aircraft may not be concluded before its results announcement
Read moreGlaxoSmithKline submits regulatory application for UMEC/VI
18th Dec 2012 12:05
Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the US for UMEC/VI medicine, used to treat chronic obstructive pulmonary disease (COPD). UMEC/VI is an investigational once-daily LAMA/LABA combination medicine. It includes properties, umeclidi
Read moreWednesday broker round-up UPDATE
12th Dec 2012 07:25
AMEC: Credit Suisse reduces target price from 1300p to 1250p reiterating an outperform rating. Anglo American: Barclays upgrades to equal-weight with a target price of 1970p. Ashtead Group: Barclays raises target price from 352p to 434p and reiterates an overweight rating. ASOS: HSBC raises targe
Read moreMonday broker round-up UPDATE
3rd Dec 2012 07:16
ARM Holdings: Exane BNP Paribas upgrades from neutral to buy. Ashtead Group: Bank of America starts with a target price of 460p and a buy recommendation. AstraZaneca: Berenberg raises target price from 3080p to 3100p; hold recommendation kept. Balfour Beatty: Investec reduces target price from 21
Read moreTuesday tips round-up: GlaxoSmithKline, Cranswick,SDL
27th Nov 2012 08:37
Last month, GlaxoSmithKline (GSK) announced a review of its European operations as sales fell 5 per cent in the third quarter, to 6.53bn pounds, a decline which could lead to significant job cuts. The drugs group said continued pressure on drug prices in austerity-hit Europe, together with lower dem
Read moreGSK plans to increase stakes in both India and Nigeria
26th Nov 2012 07:59
Pharmaceuticals giant GlaxoSmithKline has announced a voluntary open offer to increase its holding in its publicly-listed Consumer Healthcare subsidiary in India. The company also said it has come to an agreement on the terms of a proposal to increase its ownership in GlaxoSmithKline Consumer Niger
Read moreMonday broker round-up -UPDATE
12th Nov 2012 09:03
Afferro Mining Inc: Investec retains buy recommendation and target price at 107p. Antrim Energy Inc.: Westhouse Securities keeps buy recommendation and target price at 70p. ASOS: Investec ups target from 2,450p to 2,675p, buy rating kept. Aveva: Investec keeps buy rating and 2,200p target. Bovis
Read moreFTSE 100 movers: Miners provide a drag
5th Nov 2012 15:15
Mining stocks were providing a drag as investors digested the economic figures out in China overnight. The HSBC China services PMI fell from a four-month high of 54.3 to 53.5 in October, contrasting with the official services PMI from the National Bureau of Statistics this weekend which rose from 53
Read moreMonday broker round-up
5th Nov 2012 08:19
Aggreko: Goldman Sachs cuts target from 3,692p to 3,460p, conviction buy rating kept. Asian Citrus: Seymour Pierce keeps buy rating and 50p target; BG Group: Nomura keeps buy rating and 1,600p target. BP: HSBC cuts target from 550p to 530p, overweight rating kept. Brewin Dophin: RBC Capital Mark
Read moreLondon close: Sandy aftermath and Eurozone concerns sink stocks
31st Oct 2012 16:37
The resumption of trading on Wall Street after a two-day closure and a meeting of Eurozone finance ministers was enough to weigh on London's stock market on Wednesday, not to mention some sharp falls from heavy hitters BG Group and Barclays. US benchmarks re-opened in the red today after Hurricane
Read moreFTSE 100 movers: BG dives after slashing production guidance
31st Oct 2012 15:27
BG Group shocked the market today by cutting back production guidance as a result of a number of delays to project start-ups. It now expects full-year production will be just three per cent higher than in 2011, while 2013 output is not expected to show any growth at all. The firm also announced th
Read moreGlaxo comes up short as European concerns continue
31st Oct 2012 11:59
Pharmaceuticals giant Glaxo's third quarter figures came in short of expectations on most fronts, while full year sales are now expected to be little changed from 2011. Against expectations of earnings per share (EPS) of 28.7p, GlaxoSmithKline delivered 26.5p, down 13% year-on-year or down 11% on a
Read more